- Home
- IPM vs BNR Comparison
IPM vs BNR Comparison
Compare IPM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPM
- BNR
- Stock Information
- Founded
- IPM 2005
- BNR 2014
- Country
- IPM United States
- BNR China
- Employees
- IPM N/A
- BNR N/A
- Industry
- IPM
- BNR Medical Specialities
- Sector
- IPM
- BNR Health Care
- Exchange
- IPM NYSE
- BNR Nasdaq
- Market Cap
- IPM 27.9M
- BNR 29.1M
- IPO Year
- IPM N/A
- BNR 2020
- Fundamental
- Price
- IPM $1.98
- BNR $4.22
- Analyst Decision
- IPM Strong Buy
- BNR
- Analyst Count
- IPM 1
- BNR 0
- Target Price
- IPM $6.00
- BNR N/A
- AVG Volume (30 Days)
- IPM 35.3K
- BNR 29.7K
- Earning Date
- IPM 08-13-2025
- BNR 08-21-2025
- Dividend Yield
- IPM N/A
- BNR N/A
- EPS Growth
- IPM N/A
- BNR N/A
- EPS
- IPM N/A
- BNR N/A
- Revenue
- IPM $6,344,746.00
- BNR $72,112,038.00
- Revenue This Year
- IPM $1,957.49
- BNR $136.32
- Revenue Next Year
- IPM $17.96
- BNR N/A
- P/E Ratio
- IPM N/A
- BNR N/A
- Revenue Growth
- IPM 14.16
- BNR 0.53
- 52 Week Low
- IPM $1.52
- BNR $2.18
- 52 Week High
- IPM $5.50
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- IPM N/A
- BNR 63.77
- Support Level
- IPM N/A
- BNR $3.06
- Resistance Level
- IPM N/A
- BNR $3.50
- Average True Range (ATR)
- IPM 0.00
- BNR 0.21
- MACD
- IPM 0.00
- BNR 0.05
- Stochastic Oscillator
- IPM 0.00
- BNR 95.65
About IPM INTELLIGENT PROTECTION MANAGEMENT
Intelligent Protection Management Corp is a communications software innovator that powers multimedia social applications.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.